Enhertu receives U.S. Priority Review as a post-neoadjuvant therapy for patients with early-stage HER2-positive breast cancer. AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment…
European Commission Approves Zynyz® (retifanlimab) as a First-Line Treatment for Patients with Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Incyte has announced that the European Commission has granted approval for Zynyz (retifanlimab) to be used in combination with…
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus Mirum Pharmaceuticals, Inc. a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase…
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results Silence Therapeutics plc, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full…
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the Licensee”) informed Xencor, Inc. (the “Company”) that it…
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced U.S. Food and Drug Administration…
Liberate Medical Completes Enrollment of 250-Patient PREVENT Pivotal Trial Evaluating VentFree® Respiratory Muscle Stimulator Liberate Medical, a clinical-stage medical device company developing breakthrough neuromuscular electrical stimulation (NMES) technology for mechanically ventilated ICU patients, today announced the completion of enrollment in…
Innovate 32 Partners with Crestview Dental and Cedar Street Family Dentistry, Continuing Momentum in East Tennessee Innovate 32 a growth-oriented dental services organization, today announced new partnerships with Crestview Dental and Cedar Street Family Dentistry, two highly respected general dentistry…
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Amylyx Pharmaceuticals, Inc. today reported financial and business results for the fourth quarter and full year ended December 31, 2025. 2025 was a year of meaningful advancement for Amylyx’s…
Royalty Pharma Names Kenneth Sun as Senior Vice President and Head of Asia, Strengthening Its Global Expansion Strategy and Regional Presence Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of…
Genentech Announces Positive Phase III Results for Fenebrutinib in RMS, Paving the Way for Regulatory Submission Why is the search for effective treatments for multiple sclerosis (MS) more urgent than ever? Genentech, a member of the Roche Group, has announced…
Positive Phase 3 Trial Results Signal New Standard of Care for Bladder Cancer Patients Is the current standard of care for muscle-invasive bladder cancer (MIBC) about to change? Pfizer Inc. and Astellas Pharma Inc. have announced groundbreaking results from the…